Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss), dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Lynch syndrome and the tag subtype-page.
Shares MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss), Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval, Lynch syndrome, Tumour-agnostic (tissue-agnostic) approval and the tag subtype-page.
Shares Ipilimumab, Nivolumab, Pembrolizumab and the tag subtype-page.
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Ipilimumab, Nivolumab, Liquid biopsy (ctDNA) and the tag subtype-page.
Shares Lynch syndrome, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Germline (hereditary) testing, Pembrolizumab and the tag subtype-page.
Shares Nivolumab, Liquid biopsy (ctDNA), Pembrolizumab and the tag subtype-page.
Shares Tremelimumab, Durvalumab, Pembrolizumab and the tag subtype-page.
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Pembrolizumab and the tag subtype-page.
The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.